RU2008140661A - APPLICATION OF ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES IN A PATIENT WITH AN INadequate RESPONSE TO TNF-ALPH INHIBITOR - Google Patents
APPLICATION OF ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES IN A PATIENT WITH AN INadequate RESPONSE TO TNF-ALPH INHIBITOR Download PDFInfo
- Publication number
- RU2008140661A RU2008140661A RU2008140661/14A RU2008140661A RU2008140661A RU 2008140661 A RU2008140661 A RU 2008140661A RU 2008140661/14 A RU2008140661/14 A RU 2008140661/14A RU 2008140661 A RU2008140661 A RU 2008140661A RU 2008140661 A RU2008140661 A RU 2008140661A
- Authority
- RU
- Russia
- Prior art keywords
- mammal
- antibody
- use according
- week
- response
- Prior art date
Links
Abstract
1. Применение антитела, которое связывается с CD20, для производства лекарственного средства для лечения ревматоидного артрита у млекопитающего с неадекватным ответом на ингибитор TNFα, при котором млекопитающее имеет ACR50 ответ на 24-й неделе, ACR70 ответ на 24-й неделе или не имеет прогрессивного развития эрозий на 24-й неделе и далее. ! 2. Применение по п.1, в котором млекопитающим является человек. ! 3. Применение по п.1, в котором антитело не конъюгировано с цитотоксическим агентом. ! 4. Применение по п.1, в котором антителом является ритуксимаб. ! 5. Применение по п.1, в котором антитело является гумманизированным антителом 2Н7 v16, содержащим вариабельные домены, представленные SEQ ID Nos. 1 и 2. ! 6. Применение по п.1, при котором лекарственное средство применяется для лечения млекопитающего в способе, который, по существу, заключается во введении млекопитающему антагониста. ! 7. Применение по п.1, при котором антитело вводится в качестве двух внутривенных доз по 1000 мг. ! 8. Применение по п.1, при котором млекопитающее дополнительно получают сопутствующую терапию метотрексатом (МТХ). ! 9. Применение по п.8, при котором млекопитающее дополнительно лечат кортикостероидами. ! 10. Применение по п.9, при котором кортикостероиды включают метилпреднизолон и преднизолон. 1. The use of an antibody that binds to CD20 for the manufacture of a medicament for the treatment of rheumatoid arthritis in a mammal with an inadequate response to a TNFα inhibitor in which the mammal has an ACR50 response at week 24, an ACR70 response at week 24, or is not progressive the development of erosion in the 24th week and beyond. ! 2. The use according to claim 1, in which the mammal is a human. ! 3. The use according to claim 1, in which the antibody is not conjugated to a cytotoxic agent. ! 4. The use according to claim 1, in which the antibody is rituximab. ! 5. The use according to claim 1, in which the antibody is a humanized antibody 2H7 v16 containing the variable domains represented by SEQ ID Nos. 1 and 2.! 6. The use according to claim 1, wherein the drug is used to treat a mammal in a method which essentially consists in administering an antagonist to the mammal. ! 7. The use according to claim 1, wherein the antibody is administered as two intravenous doses of 1000 mg. ! 8. The use according to claim 1, in which the mammal additionally receive concomitant therapy with methotrexate (MTX). ! 9. The use of claim 8, wherein the mammal is further treated with corticosteroids. ! 10. The use of claim 9, wherein the corticosteroids include methylprednisolone and prednisolone.
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/461,481 | 2003-04-09 | ||
US46148106P | 2006-04-09 | 2006-04-09 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005134394/14A Division RU2358762C9 (en) | 2003-04-09 | 2004-04-06 | Treatment of autoimmune diseases in patient suffering from inadequate response to tnf-alpha inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2008140661A true RU2008140661A (en) | 2010-04-20 |
RU2489166C2 RU2489166C2 (en) | 2013-08-10 |
Family
ID=46274896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008140661/15A RU2489166C2 (en) | 2006-04-09 | 2008-10-14 | Using antibodies for treating autoimmune diseases in patient with inadequate response to tnf-alpha inhibitor |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2489166C2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2639540C2 (en) * | 2011-08-10 | 2017-12-21 | Ланкенау Инститьют Фо Медикал Ресёрч | Methods and compositions for autoimmune and inflammatory diseases treatment |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2724469C2 (en) | 2018-10-31 | 2020-06-23 | Закрытое Акционерное Общество "Биокад" | Monoclonal antibody which specifically binds to cd20 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2203363A1 (en) * | 1994-10-25 | 1996-05-02 | Jean-Yves Marcel Paul Bonnefoy | Binding agents to cd23 |
US5677189A (en) * | 1995-06-29 | 1997-10-14 | Oncomembrane, Inc. | Method for quantifying sphingosine and for diagnosing platelet activation |
JP2001058956A (en) * | 1999-08-19 | 2001-03-06 | Welfide Corp | Autoimmune disease-preventing and treating agent |
-
2008
- 2008-10-14 RU RU2008140661/15A patent/RU2489166C2/en active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2639540C2 (en) * | 2011-08-10 | 2017-12-21 | Ланкенау Инститьют Фо Медикал Ресёрч | Methods and compositions for autoimmune and inflammatory diseases treatment |
Also Published As
Publication number | Publication date |
---|---|
RU2489166C2 (en) | 2013-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018233032B2 (en) | TEC family kinase inhibitor adjuvant therapy | |
US6623736B2 (en) | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders | |
Tanaka et al. | A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus | |
RS52471B (en) | Dosage regimen for the treatment of a traumatic brain injury with progesterone | |
US6471961B1 (en) | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders | |
JP2004512262A5 (en) | ||
JP2014114288A5 (en) | ||
JP2002537356A (en) | Tumor necrosis factor antagonist for treatment of neuropathy | |
RU2007132181A (en) | ANTI-CANCER MEDICINE CONTAINING α, α, α-TRIFTORTIMIDINE AND A THIMIDINFOSPHORILYLASE INHIBITOR | |
CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
WO2018223923A1 (en) | Use of pd-1 antibody combined with vegf ligand or vegf receptor inhibitor in preparing drug for treating tumor | |
PE20061075A1 (en) | ANTI-VEGF ANTIBODIES AS ANTIANGIOGENIC AGENTS TO TREAT AUTOIMMUNE DISEASES IN PATIENTS IN WHOM PREVIOUS THERAPY FAILED | |
JP2020508317A5 (en) | ||
JP2015172060A5 (en) | ||
JP2018515493A5 (en) | ||
JP2022160685A5 (en) | ||
RU2014117510A (en) | TREATMENT OF RHEUMATOID ARTHRITIS | |
CN114286828A (en) | Dosing regimens and combination therapies for multispecific antibodies targeting B cell maturation antigens | |
Keystone | B cells in rheumatoid arthritis: from hypothesis to the clinic | |
RU2016149316A (en) | TREATMENT OF RHEUMATOID ARTHRITIS | |
RU2011117293A (en) | COMPOSITION FOR TREATING A DISEASE | |
RU2008140661A (en) | APPLICATION OF ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES IN A PATIENT WITH AN INadequate RESPONSE TO TNF-ALPH INHIBITOR | |
AR068531A1 (en) | FIXED DOSE BY ONE INJECTION FOR OCRELIZUMAB (2H7). USE OF RITUXIMAB. PHARMACEUTICAL FORMULATION KIT | |
RU2394596C2 (en) | Combined therapy by radioactively marked antibody anti-cd20 in treatment of b-cellular lymphoma | |
KR20180017145A (en) | Treatment of pruritus |